Aiforia Technologies Plc appoints a new Vice President of Marketing who brings international experience in various commercial positions both in the field of tissue diagnostics and targeted therapies for cancer.
As of February 20th, Manuel Ahlsten has been appointed as Vice President of Marketing. In this position, he leads the strategic direction and execution of marketing efforts both in clinical and preclinical settings. In this role, Manuel aims to accelerate the company's growth strategy by supporting sales efforts and building awareness for Aiforia and its products.
”We’re seeing a paradigm shift in how pathology images analyzed as glass slides are increasingly being examined on a computer instead of a microscope. This has paved the way for powerful deep-learning artificial intelligence algorithms to be used in image analysis,” says Ahlsten. “Pathology sample numbers are on the rise. Aiforia's AI models can streamline laboratory workflows, improve the accuracy of analyses and ease the workload of pathologists. I feel privileged to join Aiforia, and I’m committed to our mission.”
Manuel has previously worked in some of the largest biotechnology companies in the world. He spent several years in the United States working in the global marketing of pathology products for Roche. Before joining Aiforia, he worked with lung cancer therapies at AstraZeneca as a manager for Nordic sales teams.
“We’re pleased to welcome Manuel as the marketing team lead. His international marketing experience, coupled with an understanding of both tissue diagnostics and oncology, brings valuable knowledge and skills to Aiforia. Manuel’s sales and marketing leadership experience also supports seamless collaboration of these key functions at Aiforia,” says Jukka Tapaninen, CEO of Aiforia Technologies Plc.
Jukka Tapaninen, CEO, Aiforia Technologies Plc, tel. +33 61 041 6686
UB Securities Ltd, tel. +358 9 25 380 225